Literature DB >> 18539601

Juglone inactivates cysteine-rich proteins required for progression through mitosis.

Claudia Fila1, Corina Metz, Peter van der Sluijs.   

Abstract

The parvulin peptidyl-prolyl isomerase Pin1 catalyzes cis-trans isomerization of p(S/T)-P bonds and might alter conformation and function of client proteins. Since the trans conformation of p(S/T)-P bonds is preferred by protein phosphatase 2A (PP2A), Pin1 may facilitate PP2A-mediated dephosphorylation. Juglone irreversibly inhibits parvulins and is often used to study the function of Pin1 in vivo. The drug prevents dephosphorylation of mitotic phosphoproteins, perhaps because they bind Pin1 and are dephosphorylated by PP2A. We show here however that juglone inhibited post-mitotic dephosphorylation and the exit of mitosis, independent of Pin1. This effect involved covalent modification of sulfhydryl groups in proteins essential for metaphase/anaphase transition. Particularly cytoplasmic proteins with a high cysteine content were vulnerable to the drug. Alkylation of sulfhydryl groups altered the conformation of such proteins, as evidenced by the disappearance of antibody epitopes on tubulin and the mitotic checkpoint component BubR1. The latter activates the anaphase-promoting complex/cyclosome, which degrades regulatory proteins, such as cyclin B1 and securins, and is required for mitotic exit. Indeed, juglone-treated cells failed to assemble a mitotic spindle, which correlated with perturbed microtubule dynamics, loss of immunodetectable tubulin, and formation of tubulin aggregates. Juglone also prevented degradation of cyclin B1, independently of the Mps1-controlled mitotic spindle checkpoint. Since juglone affected cell cycle progression at several levels, more specific drugs need to be developed for studies of Pin1 function in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539601     DOI: 10.1074/jbc.M710264200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Prolyl isomerase Pin1 negatively regulates AMP-activated protein kinase (AMPK) by associating with the CBS domain in the γ subunit.

Authors:  Yusuke Nakatsu; Misaki Iwashita; Hideyuki Sakoda; Hiraku Ono; Kengo Nagata; Yasuka Matsunaga; Toshiaki Fukushima; Midori Fujishiro; Akifumi Kushiyama; Hideaki Kamata; Shin-Ichiro Takahashi; Hideki Katagiri; Hiroaki Honda; Hiroshi Kiyonari; Takafumi Uchida; Tomoichiro Asano
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

2.  Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Authors:  Prashant Rajbhandari; Greg Finn; Natalia M Solodin; Kiran K Singarapu; Sarata C Sahu; John L Markley; Kelley J Kadunc; Stephanie J Ellison-Zelski; Anastasia Kariagina; Sandra Z Haslam; Kun Ping Lu; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

3.  A Molecular Insight of the Role of PIN-1 Promoter Polymorphism (- 667C > T; rs2233679) in Chronic Kidney Disease Patients with Secondary Hyperparathyroidism.

Authors:  Digishaben D Patel; Deepak Parchwani; Uday Vachhani; Tanishk Parchwani; Pratik Raghavani; Ajay Rajput; Sagar Dholariya; Ragini Singh
Journal:  Indian J Clin Biochem       Date:  2021-08-03

4.  The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism.

Authors:  Morris Nechama; Takafumi Uchida; Irit Mor Yosef-Levi; Justin Silver; Tally Naveh-Many
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

5.  Peptidyl-prolyl isomerase 1 regulates protein phosphatase 2A-mediated topographic phosphorylation of neurofilament proteins.

Authors:  Parvathi Rudrabhatla; Wayne Albers; Harish C Pant
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

6.  Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappaB family.

Authors:  Gaofeng Fan; Yongjun Fan; Nupur Gupta; Isao Matsuura; Fang Liu; Xiao Zhen Zhou; Kun Ping Lu; Céline Gélinas
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

7.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

8.  Prolyl isomerase Pin1 and protein kinase HIPK2 cooperate to promote cortical neurogenesis by suppressing Groucho/TLE:Hes1-mediated inhibition of neuronal differentiation.

Authors:  R Ciarapica; L Methot; Y Tang; R Lo; R Dali; M Buscarlet; F Locatelli; G del Sal; R Rota; S Stifani
Journal:  Cell Death Differ       Date:  2013-11-22       Impact factor: 15.828

9.  Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.

Authors:  Christian Dubiella; Benika J Pinch; Kazuhiro Koikawa; Daniel Zaidman; Evon Poon; Theresa D Manz; Behnam Nabet; Shuning He; Efrat Resnick; Adi Rogel; Ellen M Langer; Colin J Daniel; Hyuk-Soo Seo; Ying Chen; Guillaume Adelmant; Shabnam Sharifzadeh; Scott B Ficarro; Yann Jamin; Barbara Martins da Costa; Mark W Zimmerman; Xiaolan Lian; Shin Kibe; Shingo Kozono; Zainab M Doctor; Christopher M Browne; Annan Yang; Liat Stoler-Barak; Richa B Shah; Nicholas E Vangos; Ezekiel A Geffken; Roni Oren; Eriko Koide; Samuel Sidi; Ziv Shulman; Chu Wang; Jarrod A Marto; Sirano Dhe-Paganon; Thomas Look; Xiao Zhen Zhou; Kun Ping Lu; Rosalie C Sears; Louis Chesler; Nathanael S Gray; Nir London
Journal:  Nat Chem Biol       Date:  2021-05-10       Impact factor: 15.040

10.  Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.

Authors:  Ryuhei Kanaoka; Akifumi Kushiyama; Yasuyuki Seno; Yusuke Nakatsu; Yasuka Matsunaga; Toshiaki Fukushima; Yoshihiro Tsuchiya; Hideyuki Sakoda; Midori Fujishiro; Takeshi Yamamotoya; Hideaki Kamata; Akio Matsubara; Tomoichiro Asano
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.